Amgen to present psoriasis data at European Academy Of Dermatology And Venereology

[Fred]

Amgen the makers of Enbrel and Brodalumab will be presenting several studies at the 23rd Congress of the European Academy of Dermatology and Venereology (EADV) in Amsterdam, Oct. 8-12, 2014.

Brodalumab data to be presented include an exploratory analysis of the Phase 2 trial evaluating efficacy and safety of brodalumab in moderate-to-severe plaque psoriasis patients with prior biologic exposure, along with an analysis from the open-label extension study of that same Phase 2 study evaluating patient response to treatment after nearly three years. Brodalumab is being co-developed by Amgen and AstraZeneca. Kyowa Hakko Kirin, which has an exclusive license to develop and commercialize brodalumab in Japan, China and certain other Asian countries, will present efficacy and safety data from its Phase 2 study evaluating brodalumab in Japanese patients with moderate-to-severe plaque psoriasis.

ENBREL data focus on step-down dosing compared with a high-dose regimen and patient-reported outcomes of treatment with ENBREL compared to treatment with ENBREL in combination with topical therapies. Additional data include the functional equivalence of proposed biosimilar ABP 501 to adalimumab and an analysis of the incidence of symptoms such as itching and pain in patients with psoriasis.

Source: NO LINKS ALLOWED

More on Enbrel (etanercept) and Brodalumab phase 3 results

[jiml]

Thanks Fred that's another interesting article,

[Fred]

Thanks Fred that's another interesting article,

You're welcome Jim, maybe you could go as our roving reporter. Mmmmmm wonder if Caroline could offer you a room and take you on her bike.

[jiml]

Thanks Fred that's another interesting article,

You're welcome Jim, maybe you could go as our roving reporter. Mmmmmm wonder if Caroline could offer you a room and take you on her bike.

I can dream